Hypoxia, a subnormal oxygen concentration in cells is an important consideration in pharmacology because (*i*) altered cellular function may affect the therapeutic effectiveness of an agent, (*ii*) therapeutic agents may potentiate or protect against hypoxic pathology, (*iii*) hypoxia may increase or decrease drug-induced toxicity, and (*iv*) may alter the rate of drug metabolism and thus the effective therapeutic dose[@ref1]. The liver is the most important site for systemic drug metabolism. Phase I (oxidation, reduction and hydrolysis) and phase II (conjugation) reactions convert lipophilic drugs into more polar and hence more readily excreted metabolites. The rate of metabolism of lipophilic drugs is the most important factor affecting the intensity and duration of their action[@ref2].

The role of hypoxia in modulating drug metabolism has been largely investigated *in vitro* and in animal studies. A few studies conducted in men exposed to high altitude hypoxia are inconclusive. In one study[@ref3] healthy subjects who lived at sea level were exposed to altitude induced hypoxia for 7 days at 4559 m above sea level. Hepatic CYP enzyme activity was measured before departure, at 24 and 96 h after arrival to high altitude location and at 1 month after return to sea level. No clinically significant effect of acute hypoxia on CYP enzymes was observed. In another study in human patients of chronic hypoxemia (PaO~2~ \< 55 mmHg), antipyrine half-life was increased by 20 per cent indicating slower biotransformation of the drug[@ref4].

An open-label, controlled, prospective study was conducted to investigate the pharmacokinetics of sulphamethoxazole in healthy Chinese male volunteers at low and high altitudes[@ref5].

Significant changes were reported in the disposition of sulphamethoxazole in these subjects after either acute or chronic exposure to an altitude of \~3780 m in comparison to those residing at an altitude of \~400 m.

It has been reported that no substantial change occurs in cytochrome P450 and b5 in mice subjected to acute hypoxia[@ref6]. Oxygen-requiring processes of hepatic heme and drug metabolism remain well maintained during hypoxia[@ref7]. A decrease in hepatic cytochrome P450 content in rats submitted to 5,500 m simulated altitude for 35 days has been reported but no change in rats subjected to 4400 m for 6 to 8 months was observed[@ref8].

The influence of moderate hypoxia or hypercapnia on salbutamol kinetics and its hypokaliaemic effect, following its administration through the intravenous, intra-tracheal, and oral routes was studied[@ref9], concluding that salbutamol kinetics and dynamics can be altered by hypoxia and hypercapnia. Thallium kinetics was studied during normoxia and hypoxia in cultured chick ventricular cells[@ref10]. The results showed that cellular accumulation of thallium and the rate of washout of thallium were minimally decreased by hypoxia independent of blood flow. The effect of hypoxia and hyperoxia on the pharmacokinetics of propofol emulsion, hepatic blood flow and arterial ketone body ratio in the rabbit has been studied[@ref11], indicating that hypoxia produced an accumulation of propofol in blood and reduced its clearance which could be due to decreased hepatic blood flow and low energy change in the liver.

In this study, an attempt was made to assess effect of hypobaric hypoxia on several commonly used drugs in rats and rabbits exposed to chronic intermittent hypoxia.

Material & Methods {#sec1-1}
==================

*Animals and experimental design*: Male Sprague Dawley albino rats were used to study the effect of hypoxia on Rightening Reflex (ability to turn spontaneously to the "on quarters" position when placed on the back) and male New Zealand White Rabbits were used to study the plasma clearance of drugs under hypoxic conditions. The study was conducted in n0 eurochemistry and h0 aematology l0 aboratories of Defence Institute of Physiology and Allied Sciences (DIPAS), Delhi.

Thirty six male Sprague Dawley albino rats weighing 200-250 g and 48 male New Zealand White rabbits weighing 1.5 to 3.0 kg, bred at Institute\'s animal facility in room maintained at 24 ± 0.5°C with 12 h light and dark cycle were used for the study. The rats were fed on standard pelleted diet supplied by Lipton India Ltd., and had free access to food and water. Rabbits were given green vegetables and pelleted diets. All the experiments were approved by Institutional Animal Ethics Committee (IAEC).

*Exposure protocol*: Exposure was carried out in a decompression chamber (Seven Star, India) maintained at 10 ± 2.5°C temperature and 65 ± 10 per cent relative humidity. Airflow rate was kept at 5.0 ± 0.5 lit/min.

For sleeping time study, hypoxia group rats were exposed to 282.4 mm Hg (376 mbar) pressure equivalent to 25000 feet for 3 h/day for 7 days. Control group was exposed to normal room air. For plasma clearance study rabbits were exposed to hypobaric hypoxia at 429 mm Hg (555 mbar) pressure equivalent to 15000 feet altitude for 5 h/day for 7 days. In control group rabbits were exposed to room air (normoxia).

*Drug induced paralysis/sleeping time assessment (Experiment I)*: Drug induced sleeping time was studied immediately after termination of the last exposure. Rats (n=6) exposed to intermittent hypoxia and normoxia (n=6) were injected intra-peritoneally either zoxazolamine (60 mg/kg bw), pentobarbitone (50 mg/kg bw) or thiopentone sodium (40 mg/kg bw). Separate groups of rats were used for testing of each drug. The time of injection, time of loss and time of gain rightening reflex were recorded with the help of a stopwatch. Duration of sleeping time was computed as the time interval between loss and gain of rightening reflex.

*Plasma clearance of drugs (Experiment II)*: In the present study, acetyl salicylic acid (25 mg/kg bw), gentamicin (10 mg/kg bw), phenobarbitone (30 mg/kg bw) and acetazolamide (25 mg/kg bw) clearance were assessed to study in vivo drug metabolizing status of hypoxia exposed animals.

Rabbits divided in two groups - hypoxia and normoxia (n=6 each) were injected either of the above mentioned drug in the amount specified by intravenous route in a peripheral ear vein, immediately after the last exposure. Blood sample (0.5 ml) was drawn from a vein in opposite ear and taken as zero hour sample. Thereafter blood samples were drawn after 30 min, 1, 2, 3, 5 and 24 h. Amount of the injected drug remaining in plasma was measured. Acetyl salicylic acid was measured spectrophotometerically on Beckman DU 50 spectrophotometer (Beckman Coulter Inc. USA) by trinder reagent[@ref12]. Gentamicin and phenobarbitone were measured by Enzyme Immuno Assay kits (Dade Behring Ltd, UK). Acetazolamide concentration in plasma samples was measured by HPLC using UV detector[@ref13].

Separate sets of animals were used for testing of each drug. Pharmacokinetic parameters were computed by plotting drug concentration versus time curve on semi log scale. Regression analysis was done by GraphPad Prism (GraphPad Software Inc., San Diego, CA). Zero time concentrations were determined by extrapolating the regression line to Y axis. The values were depicted as mean ± SD. Data were analysed by s0 tudent\'s t test.

Results {#sec1-2}
=======

*Experiment I*: Rats exposed to intermittent hypobaric hypoxia for 7 days showed quicker loss of rightening reflex in response to zoxazolamine (144.9 ± 17.5 in hypoxia vs 160.6 ± 39.3 sec in control rats), pentobarbitone (130.6 ± 8.2 in hypoxia vs 139.6 ± 2.1 sec in control rats) and thiopentone sodium (124.6 ± 7.7 in hypoxia vs 107.0 ± 4.0 sec in control rats) as compared to rats exposed to normoxia, but differences were not significant ([Table](#T1){ref-type="table"}). There was a significant (*P*\<0.05) delay in regaining rightening reflex in response to pentobarbitone and thiopentone sodium indicating prolonged duration of anaesthetic effect of these drugs in hypoxic animals.

###### 

Effect of hypoxia on *in vivo* drug metabolism in terms of drug action (sleeping time)
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*Experiment II*: The half life (t~1/2~) is the time taken for the concentration of the drug in plasma to decline to half the starting concentration. Removal of acetyl salicylic acid from the plasma was computed as the first- order kinetics. Mean ± SD of half life (t~1/2~) of acetyl salicylic acid computed from log linear curve of concentration versus sampling time were 5.69 ± 1.02 h for control rabbits and 7.63 ± 0.84 h for hypoxia exposed rabbits ([Fig. 1](#F1){ref-type="fig"}). Elimination rate constant (k~el~), can be determined from the slope of the log concentration- time curve and volume of distribution (V~d~), is the volume of body fluid in which the drug is uniformly distributed at the concentration found in the plasma. Elimination rate constant (0.095 ± 0.01 in hypoxic vs 0.144 ± 0.032 in control animals; *P*\<0.01) ([Fig. 2](#F2){ref-type="fig"}) and volume of distribution (806.1 ± 122.1 in hypoxic vs 1071.1 ± 125.1 ml/ kg bw in control animals; *P*\<0.01) ([Fig. 3](#F3){ref-type="fig"}) of acetyl salicylic acid were 34 and 24.7 per cent lower in hypoxic animals compared to the control group, respectively. Total plasma clearance, the volume of plasma from which the drug is totally eliminated in a unit time was significantly (*P*\<0.001) lower for acetyl salicylic acid in hypoxia (72.3 ± 7.0 ml/kg/h) exposed rabbits than in control (155.2 ± 39.4 ml/kg/h) group ([Fig. 4](#F4){ref-type="fig"}).

![Half life (t1/2). A significant increase in half life of acetylsalicylic acid, gentamicin and acetazolamide was observed in hypoxia group than control. Significance level set at *P*\<0.05. \**P*\<0.05; \# *P*\<0.01 compared to respective control. Values are mean ± SD (n=6).](IJMR-135-211-g002){#F1}

![Elimination rate constant (kel). The bar diagram shows a significant decrease in elimination rate constant of acetylsalicylic acid and gentamicin in hypoxia exposed rabbits. Significance level set at *P*\<0.05. \#*P*\<0.01; \*\**P*\<0.001 compared to respective control.](IJMR-135-211-g003){#F2}

![Volume of distribution (Vd). The volume of distribution significantly decreased in case of acetylsalicylic acid in hypoxia exposed group whereas, a significant increment was observed for gentamicin and acetazolamide drugs. Significance level set at *P*\<0.05. \#*P*\<0.01; \*\**P*\<0.001 compared to respective control.](IJMR-135-211-g004){#F3}

![Plasma clearance (ml/kg/h). A significant decrease in plasma clearance of acetylsalicylic acid and phenobarbitone in hypoxia group was observed in comparison to control group whereas, acetazolamide plasma clearance significantly increased in hypoxia group. Significance level set at *P*\<0.05. \**P*\<0.05; \*\**P*\<0.001 compared to respective control.](IJMR-135-211-g005){#F4}

Elimination of aminoglycosides like gentamicin occurs almost entirely by glomerular filtration. The half-life (t~1/2~) for gentamicin in control rabbits (1.11 ± 0.65 h) was significantly lower (*P*\<0.05) than that of hypoxia exposed rabbits (1.80 ± 0.17 h) ([Fig. 1](#F1){ref-type="fig"}). Elimination rate constant for gentamicin was also significantly (*P*\<0.001) lower in hypoxic rabbits (0.389 ± 0.041) than that of control (0.909 ± 0.051) rabbits ([Fig. 2](#F2){ref-type="fig"}). In hypoxia exposed (241.4 ± 12.4 ml/ kg bw) animals apparent volume of distribution for gentamicin was significantly more (*P*\<0.001) than in control (163.9 ± 13.9 ml/ kg bw) rabbits ([Fig. 3](#F3){ref-type="fig"}) and total plasma clearance rate in hypoxic rabbits (83.9 ± 6.2 ml/kg/h) was 11% lower than control (94.3 ± 10.9 ml/kg/h) rabbits ([Fig. 4](#F4){ref-type="fig"}).

Acetazolamide is excreted unchanged and its clearance is affected by renal function. The pharmacokinetic profile of this drug was similar to gentamicin. Elimination rate constant for acetazolamide in hypoxia-exposed (0.527 ± 0.028) animals was lower (27%) than control (0.720 ± 0.188) animals ([Fig. 2](#F2){ref-type="fig"}). Median plasma clearance time (t~1/2~) of acetazolamide in hypoxia-exposed rabbits was significantly (*P*\<0.05) prolonged (28%), as compared to control rabbits ([Fig. 1](#F1){ref-type="fig"}). Volume of distribution showed significant (*P*\<0.001) increase as hypoxic animals as compared to control ([Fig. 3](#F3){ref-type="fig"}).

Prolonged plasma half-life (8.01 ± 2.40 in hypoxia vs 7.28 ± 3.33 h in control) ([Fig. 1](#F1){ref-type="fig"}), decreased rate of clearance (66.6 ± 10.9 in hypoxia vs 96.7 ± 27.2 ml/kg/h in control) ([Fig. 4](#F4){ref-type="fig"}) and decreased volume of distribution (760.8 ± 238.4 in hypoxia Vs 950.1 ± 178.5 ml/kg bw in control) ([Fig. 3](#F3){ref-type="fig"}), pointed out slowed metabolism and increased binding of the drug to plasma proteins and its entry to tissue compartments as well.

Discussion {#sec1-3}
==========

Zoxazolamine is a potent muscle relaxant, which is metabolically inactivated by CYP1A1/2 enzyme activity (and to a lesser extent CYP2E1). It has also been used as a functional test to evaluate chemicals for their ability to inhibit CYP1A1/2 enzyme activity *in vivo*[@ref14][@ref15]. Pentobarbital is a short acting barbiturate approved as a short-term hypnotic and veterinary use as an anesthetic[@ref16]. Therefore, sleeping time test was used for preliminary investigations on whether hypoxic stress interferes with metabolism of drugs.

Significantly prolonged sleeping time with pentobarbitone and thiopentone sodium in hypoxia-exposed rats suggests slowed elimination of these drugs. Similar results have been reported earlier[@ref17] in rabbits. Also reduced rate of pentobarbital disappearance in mice during exposure to acute hypoxia suggesting depressed *in vivo* metabolism of pentobarbital and enhanced CNS sensitivity to the barbiturates have been repoprted[@ref18].

Pharmacokinetics of some of the commonly used drugs has been investigated in this study. Acetyl salicylic acid has been reported to have neuroprotective action against hypoxic hypoxia and chemical hypoxia[@ref19]. Acetazolamide is a carbonic anhydrase inhibitor and is the mainstay for prevention and treatment of acute mountain sickness[@ref20]. Gentamicin is an aminoglycoside antibiotic, used to treat many types of bacterial infections, particularly those caused by Gram-negative bacteria, and phenobarbitone is used for treatment of epileptic seizures.

Elimination of aminoglycosides after parenteral administration occurs almost entirely by glomerular filtration. We observed delay in half-life of gentamicin as well as acetazolamide. Both the drugs do not require any metabolic transformation before elimination by kidneys. The elimination half-life for gentamicin has been reported to be 1 h in rabbits which is quite similar to the values found in control rabbits in the present study. Elimination rates can be highly variable with the aminoglycoside antibi-otics in humans with normal renal function. Patients with decreased renal function can have significantly prolonged half-lives for gentamicin clearance. A significant increase in the pharmacokinetics of drugs like aminoglycosides eliminated through the kidneys may be impaired and require a different than usual dosage regimen under various physiological, pathological and environmental conditions. A decrease in body temperature is associated with a decrease in glomerular filtration rate in rats[@ref21], in other species and in humans are temperature requiring processes and hence temperature sensitive[@ref22] and may, therefore, impair the elimination of aminoglycosides. Hypoxia-ischaemia altered renal function and gentamicin pharmacokinetics. Therefore, altered renal function during hypoxia could be the reason for prolonged stay of these drugs in plasma.

Acetazolamide is distributed throughout body tissues where it may bind certain proteins such as carbonic anhydrase. Therefore, high concentrations of acetazolamide may accumulate in tissues rich in carbonic anhydrase such as erythrocytes, renal cortex[@ref23]. Slowed blood flow in some of the tissues in splanchnic region during hypoxia can also hamper clearance of these drugs. Our results did not confirm to a earlier study[@ref24], where the pharmacokinetics of acetazolamide in volunteers at sea level, on the day of arrival at high altitude (4360 m) and after 10 months of stay at this altitude was investigated. Clearance of acetazolamide was found to be faster at high altitude. The causal factors were increased uptake of the drug by erythrocytes and decreased protein binding.

Slowed clearance of acetyl salicylic acid and phenobarbitone in rabbits exposed to hypoxia in our study suggests compromised hepatic drug metabolizing capacity.

Another study carried out in rabbits subjected to acute moderate hypoxia and serum mediators such as interferon-γ, interleukin-2 and interleukin 1β, demonstrated downregulation of CYP1A1, 1A2, 2B4, 2C9 and 2C19 and up-regulation of CYP3A6[@ref25]. *Ex vivo* and *in vitro* experiments[@ref26]--[@ref27], demonstrated that hypoxia downregulates CYP1A1, CYP1A2, CYP2B6, CYP2C9 and CYP2C19 and upregulates CYP3A6, and change in hepatic CYP P450 is mediated by interferon-γ, interleukin-1β and interleukin-2. Decreased disposition of acetaminophen in rats has been reported which was due to impaired glucuronidation and sulphation reactions[@ref28]. These changes could also be induced through reduced hepatic blood flow and a lowered energy state of liver mitochondria[@ref2][@ref11]. Therefore, decreased blood flow in liver could also be responsible for inhibition of drug metabolism in our study.

In conclusion, our results suggest that intermittent hypobaric hypoxia impairs *in vivo* drug metabolizing ability in animals. These results can have serious implications in the dosage regimen, design and continuation of therapeutic measures in sojourners going to high altitude for occupational, recreational or religious purposes. Hence, care must be taken while prescribing medication to high altitude sojourners (with or without pre-existing medical conditions) as the ascent to high altitude has several deleterious effects on physiological functions and deficient metabolic activity and expression of enzymes along with factors like renal insufficiency hepatic insufficiency could lead to alteration in drug metabolism.
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